# Vedolizumab (Anti-alpha4beta7) in Subjects With HIV Infection Undergoing Analytical Treatment Interruption

> **NCT02788175** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 26 (actual)

## Conditions studied

- HIV

## Interventions

- **BIOLOGICAL:** Entyvio (Vedolizumab)

## Key facts

- **NCT ID:** NCT02788175
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-28
- **Primary completion:** 2019-03-04
- **Final completion:** 2019-03-04
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2020-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02788175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02788175, "Vedolizumab (Anti-alpha4beta7) in Subjects With HIV Infection Undergoing Analytical Treatment Interruption". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02788175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*